Format

Send to

Choose Destination
See comment in PubMed Commons below
J Cardiovasc Pharmacol Ther. 2013 Nov;18(6):505-13. doi: 10.1177/1074248413503043. Epub 2013 Sep 19.

Cardiovascular pharmacology core reviews: aspirin.

Author information

1
1Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Abstract

Acetylsalicylic acid, or aspirin, is perhaps the most well-studied drug in human history, but controversy persists regarding both optimal dose and its use in the primary prevention of atherothrombotic events. This article reviews the following: the effect of aspirin upon the cyclooxygenase pathway; clinical trials of aspirin for both secondary and primary prevention; prospective and retrospective studies of aspirin dose; the potential interaction between aspirin and ticagrelor; and the concept of aspirin resistance. It concludes with a review of major society guidelines regarding aspirin and offers a perspective on the evidence-based use of aspirin in clinical practice.

KEYWORDS:

aspirin; cardiovascular diseases; drug resistance; primary prevention; secondary prevention

PMID:
24057863
DOI:
10.1177/1074248413503043
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center